Table 4. Cost-effectiveness: base case results.
Value (discounted) | Standard therapy | Belimumab | Difference |
---|---|---|---|
Life years | 18.99 | 19.76 | 0.77 |
QALYs a | 10.78 | 11.31 | 0.538 |
Costs | € 125,234 | € 142,921 | € 17,688 |
ICUR b | € 32,859 | ||
ICER c | € 22,990 |
a QALYs: Quality Adjusted Life Years
b ICUR: Incremental Cost-Utility Ratio
c ICER: Incremental Cost-Effectiveness Ratio